Stock TH THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Theratechnologies Inc.

Equities

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 20:59:47 01/05/2024 BST 		5-day change 1st Jan Change
1.79 CAD +1.13% Intraday chart for Theratechnologies Inc. -3.24% -16.36%
04-10 Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision MT
04-10 Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug MT

Valuation

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 312.4 231 400.5 278.8 105.8 82.3 - -
Enterprise Value (EV) 1 312.4 231 400.5 278.8 105.8 82.3 82.3 82.3
P/E ratio -19.1 x -7.99 x -9.63 x -4.31 x -1.75 x -8.52 x -7.21 x -7.18 x
Yield - - - - - - - -
Capitalization / Revenue 3.72 x 2.79 x 4.46 x 2.56 x 0.96 x 0.68 x 0.64 x 0.56 x
EV / Revenue 3.72 x 2.79 x 4.46 x 2.56 x 0.96 x 0.68 x 0.64 x 0.56 x
EV / EBITDA 728 x -26 x -21.4 x -8.71 x -26.9 x 4.29 x 3.26 x 2.38 x
EV / FCF -33.5 x -13.6 x - - - 12.2 x 4.92 x 2.38 x
FCF Yield -2.98% -7.36% - - - 8.2% 20.3% 42%
Price to Book 9.46 x 57.2 x 17.5 x -9.23 x -3.51 x -2.55 x -2.65 x -4.74 x
Nbr of stocks (in thousands) 19,238 19,253 23,780 23,785 49,202 45,980 - -
Reference price 2 16.24 12.00 16.84 11.72 2.150 1.790 1.790 1.790
Announcement Date 25/02/20 25/02/21 24/02/22 28/02/23 21/02/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 84 82.66 89.73 108.7 110.5 120.3 129.3 145.7
EBITDA 1 0.4292 -8.877 -18.75 -32.01 -3.938 19.17 25.25 34.64
EBIT 1 -11.31 -22.47 -32.43 -54.2 -14.36 7.721 0.6782 -13.93
Operating Margin -13.47% -27.19% -36.14% -49.85% -13% 6.42% 0.52% -9.56%
Earnings before Tax (EBT) 1 -16.61 -28.37 -40.69 -63.56 -31.81 -10.12 -16.92 -22.01
Net income 1 -16.61 -28.37 -40.77 -64.16 -32.38 -9.244 -13.9 -19.2
Net margin -19.77% -34.32% -45.44% -59% -29.3% -7.68% -10.75% -13.18%
EPS 2 -0.8504 -1.502 -1.748 -2.721 -1.229 -0.2102 -0.2484 -0.2494
Free Cash Flow 1 -9.319 -17 - - - 6.749 16.73 34.55
FCF margin -11.09% -20.57% - - - 5.61% 12.94% 23.71%
FCF Conversion (EBITDA) - - - - - 35.2% 66.25% 99.72%
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 25/02/20 25/02/21 24/02/22 28/02/23 21/02/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: November 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 24.1 23.4 24.97 28.7 29.09 26.82 23.28 28.09 31.69 22.08 29.89 30.97 34.33 32.17 33.03
EBITDA 1 -7.07 - -15.17 - - -5.244 -8.086 2.91 6.7 -0.3357 2.672 5.723 9.549 - -
EBIT 1 -10.36 -9.735 -27.16 -7.612 -7.753 -7.285 -10.54 0.073 3.608 -3.053 2.396 3.628 5.134 2.087 2.488
Operating Margin -43% -41.6% -108.79% -26.52% -26.65% -27.16% -45.27% 0.26% 11.38% -13.82% 8.02% 11.71% 14.95% 6.49% 7.53%
Earnings before Tax (EBT) 1 -12.7 -11.36 -29.29 -10.2 -10.58 -13.94 -13.11 -0.8377 -3.624 -5.941 -2.118 -0.2337 1.133 -4.658 -4.258
Net income 1 -12.72 -11.39 -29.45 -10.41 -10.77 -14.07 -13.28 -1.008 -3.723 -6.09 -2.164 -0.5077 0.5852 -4.658 -4.258
Net margin -52.79% -48.67% -117.95% -36.27% -37.02% -52.46% -57.06% -3.59% -11.75% -27.58% -7.24% -1.64% 1.7% -14.48% -12.89%
EPS 2 -0.5141 -0.4539 -1.261 -0.4414 -0.4898 -0.5918 -0.5268 -0.0405 -0.0405 -0.1359 -0.0457 -0.0183 - -0.0950 -0.0680
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 24/02/22 13/04/22 14/07/22 13/10/22 28/02/23 12/04/23 12/07/23 26/09/23 21/02/24 10/04/24 - - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -9.32 -17 - - - 6.75 16.7 34.5
ROE (net income / shareholders' equity) -50.3% -162% - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.720 0.2100 0.9600 -1.270 -0.6100 -0.7000 -0.6800 -0.3800
Cash Flow per Share 2 -0.2300 -0.8800 -0.8000 -0.8400 -0.2900 0.1900 0.3900 0.7700
Capex 1 1.61 0.04 - 1.34 0.43 0.68 0.34 0.34
Capex / Sales 1.92% 0.05% - 1.23% 0.39% 0.57% 0.26% 0.23%
Announcement Date 25/02/20 25/02/21 24/02/22 28/02/23 21/02/24 - - -
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Theratechnologies Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.79 CAD
Average target price
6.036 CAD
Spread / Average Target
+237.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
THERATECHNOLOGIES INC. Stock Theratechnologies Inc.
-16.36% 59.81M
CSL LIMITED Stock CSL Limited
-3.93% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-16.48% 31.47B
UCB Stock UCB
+54.06% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.58% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.57% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-2.11% 7.93B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. TH Stock
  4. Financials Theratechnologies Inc.